Payment overview · 2025
General Payments
$1,822.35
96 reported records · 22 companies
Healthcare provider profile · identity verified
Matthew Dorman, MD
Allopathic & Osteopathic Physicians|Family Medicine · PALM COAST, FL · NPI 1740284439
Verified facts
What the public records show
CMS Open Payments records show Matthew Dorman, MD received $1,822.35 in general payments during 2025 across 96 reported records.
Novo Nordisk Inc accounted for 12.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Rexulti, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $234.61 | 12.9% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $231.85 | 12.7% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $214.10 | 11.8% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $213.46 | 11.7% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.10 | 8.0% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $132.39 | 7.3% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $86.17 | 4.7% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $82.20 | 4.5% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $61.43 | 3.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $54.03 | 3.0% | 3 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $47.97 | 2.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.03 | 2.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $42.01 | 2.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.96 | 2.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.01 | 1.9% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $32.21 | 1.8% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $30.98 | 1.7% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $28.64 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.65 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.59 | 1.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.94 | 0.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.02 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,822.35 | 96 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $214.10 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $204.10 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $186.42 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $154.84 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $149.14 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $132.39 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $110.76 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $92.68 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $92.68 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $86.17 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $82.20 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.77 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $75.66 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $61.43 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $54.03 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $52.42 | 3 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $47.97 | 2 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $47.97 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.03 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $42.01 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.96 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $32.21 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $30.98 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $28.64 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.75 | 2 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $27.52 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $10.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 165 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 93 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 229 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 26 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
110 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
72 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
93 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
229 | 54 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
165 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 746 | 220 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 745 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 684 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 613 | 192 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 518 | 156 |
| Pantoprazole Sodium | Pantoprazole Sodium | 496 | 150 |
| Omeprazole | Omeprazole | 451 | 134 |
| Pravastatin Sodium | Pravastatin Sodium | 434 | 122 |
| Lisinopril | Lisinopril | 420 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 385 | 126 |
| Losartan Potassium | Losartan Potassium | 367 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 331 | 107 |
| Alprazolam | Alprazolam | 324 | 113 |
| Metformin Hcl | Metformin Hcl | 318 | 96 |
| Metoprolol Tartrate | Metoprolol Tartrate | 300 | 92 |
| Gabapentin | Gabapentin | 299 | 102 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 296 | 99 |
| Methylprednisolone | Methylprednisolone | 263 | 155 |
| Oxycodone Hcl | Oxycodone Hcl | 255 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 255 | 57 |
| Simvastatin | Simvastatin | 252 | 68 |
| Glimepiride | Glimepiride | 234 | 80 |
| Ozempic | Semaglutide | 229 | 54 |
| Furosemide | Furosemide | 225 | 96 |
| Potassium Chloride | Potassium Chloride | 224 | 84 |
| Lorazepam | Lorazepam | 212 | 64 |
| Prednisone | Prednisone | 208 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 61 |
| Famotidine | Famotidine | 181 | 75 |
| Sertraline Hcl | Sertraline Hcl | 180 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 56 |
| Metformin Hcl Er | Metformin Hcl | 176 | 63 |
| Tramadol Hcl | Tramadol Hcl | 173 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 61 |
| Eliquis | Apixaban | 165 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 154 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 72 |
| Allopurinol | Allopurinol | 144 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 144 | 76 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 141 | 46 |
| Doxycycline Hyclate | Doxycycline Hyclate | 138 | 91 |
| Montelukast Sodium | Montelukast Sodium | 136 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 136 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 132 | 46 |
| Glipizide Er | Glipizide | 118 | 40 |
| Trazodone Hcl | Trazodone Hcl | 118 | 47 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 118 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 115 | 34 |
| Meloxicam | Meloxicam | 112 | 40 |
| Synthroid | Levothyroxine Sodium | 110 | 30 |
| Carvedilol | Carvedilol | 109 | 33 |
| Mirtazapine | Mirtazapine | 108 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 39 |
| Ondansetron Odt | Ondansetron | 100 | 39 |
| Valsartan | Valsartan | 100 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 98 | 70 |
| Ezetimibe | Ezetimibe | 97 | 32 |
| Fenofibrate | Fenofibrate | 96 | 27 |
| Levofloxacin | Levofloxacin | 95 | 57 |
| Xarelto | Rivaroxaban | 95 | 25 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 94 | 31 |
| Atenolol | Atenolol | 93 | 26 |
| Mounjaro | Tirzepatide | 93 | 25 |
| Donepezil Hcl | Donepezil Hcl | 92 | 27 |
| Ibuprofen | Ibuprofen | 92 | 39 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 27 |
| Clonazepam | Clonazepam | 87 | 25 |
| Fluconazole | Fluconazole | 84 | 32 |
| Clonidine Hcl | Clonidine Hcl | 83 | 39 |
| Pregabalin | Pregabalin | 82 | 38 |
| Spironolactone | Spironolactone | 81 | 34 |
| Folic Acid | Folic Acid | 78 | 27 |
| Cefdinir | Cefdinir | 72 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 20 |
| Myrbetriq | Mirabegron | 72 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 30 |
| Ibandronate Sodium | Ibandronate Sodium | 66 | 29 |
| Testosterone Cypionate | Testosterone Cypionate | 66 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 65 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 65 | 34 |
| Temazepam | Temazepam | 64 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 26 |
| Glipizide | Glipizide | 63 | 35 |
| Celecoxib | Celecoxib | 62 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 46 |
| Diazepam | Diazepam | 61 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 19 |
| Alendronate Sodium | Alendronate Sodium | 60 | 19 |
| Ketoconazole | Ketoconazole | 60 | 27 |
| Azithromycin | Azithromycin | 59 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 17 |
| Lovastatin | Lovastatin | 58 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 58 | 20 |
| Jardiance | Empagliflozin | 57 | 19 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 53 | 20 |
| Bupropion Xl | Bupropion Hcl | 53 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 16 |
| Valacyclovir | Valacyclovir Hcl | 52 | 23 |
| Lactulose | Lactulose | 50 | 23 |
| Finasteride | Finasteride | 48 | 18 |
| Mupirocin | Mupirocin | 48 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 15 |
| Nitroglycerin | Nitroglycerin | 46 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 21 |
| Naproxen | Naproxen | 45 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 16 |
| Irbesartan | Irbesartan | 44 | 12 |
| Primidone | Primidone | 44 | 11 |
| Cefuroxime | Cefuroxime Axetil | 43 | 17 |
| Farxiga | Dapagliflozin Propanediol | 43 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 43 | suppressed |
| Estradiol | Estradiol | 42 | 16 |
| Meclizine Hcl | Meclizine Hcl | 42 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 40 | 14 |
| Januvia | Sitagliptin Phosphate | 40 | 13 |
| Lidocaine | Lidocaine | 40 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 39 | 19 |
| Rexulti | Brexpiprazole | 39 | suppressed |
| Sucralfate | Sucralfate | 38 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 37 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | 12 |
| Ramipril | Ramipril | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | 13 |
| Amoxicillin | Amoxicillin | 35 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Dutasteride | Dutasteride | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 14 |
| Azelastine Hcl | Azelastine Hcl | 34 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 22 |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Bumetanide | Bumetanide | 31 | 13 |
| Topiramate | Topiramate | 31 | 14 |
| Aripiprazole | Aripiprazole | 29 | 12 |
| Baclofen | Baclofen | 29 | suppressed |
| Ciclopirox | Ciclopirox | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | 12 |
| Telmisartan | Telmisartan | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Ubrelvy | Ubrogepant | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 11 |
| Xeljanz Xr | Tofacitinib Citrate | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | 11 |
| Promethazine Hcl | Promethazine Hcl | 27 | 12 |
| Risedronate Sodium | Risedronate Sodium | 27 | 18 |
| Gemtesa | Vibegron | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 15 |
| Methocarbamol | Methocarbamol | 26 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 24 |
| Repatha Syringe | Evolocumab | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Nystatin | Nystatin | 25 | 18 |
| Propranolol Hcl | Propranolol Hcl | 25 | 12 |
| Rybelsus | Semaglutide | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | 11 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 15 |
| Metronidazole | Metronidazole | 21 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Klor-Con 10 | Potassium Chloride | 20 | 12 |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Humira Pen | Adalimumab | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Tobramycin | Tobramycin | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Budesonide Er | Budesonide | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,822.35 · 96 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Grastek, INSPIRE, JARDIANCE, JATENZO, Kerendia, Korlym, LEQVIO, Leqembi, MOUNJARO, NEFFY, NURTEC ODT, Odactra, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REXULTI, Ragwitek, Sunosi, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error